mProX™ Human MAPKAPK2 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1206	Magic™ Human MAPKAPK2 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

MAPKAPK2

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

HeLa; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Inflammation Research; Digestive and Renal Research; Cancer Research

Related Diseases

Monocytic Leukemia and Inflammatory Bowel Disease. Among its related pathways are MyD88 dependent cascade initiated on endosome and Fatty acid metabolism

Gene ID

9261

UniProt ID

P49137

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The human MAPKAPK2 gene encodes the enzyme MAP kinase-activated protein kinase 2. A member of the Ser/Thr protein kinase family is encoded by this gene. p38 MAP kinase directly phosphorylates this kinase to control it. This kinase is known to work in concert with p38 MAP kinase to facilitate a variety of cellular activities, including as nuclear export, the regulation of gene expression, stress and inflammatory responses, and cell proliferation. It was discovered that its primary direct substrate in vivo is the heat shock protein HSP27. For this gene, two transcript variants encoding two distinct isoforms have been discovered. The customized MAPKAPK2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat David

For MAPKAPK2 drug discovery, this is a good choice. Apr 15 2022

chat Verified Customer

chat Deborah

The cell line is ideal for helping to detect MAPKAPK2. Jan 30 2020

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 p38α-dependent phosphorylation of MAPKAPK2 in response to TNFα.

After being treated with 15 ng/ml TNFα, HeLa cells were subjected to immunoblotting at different periods to assess p38α and MAPKAPK2 activation. Different doses of p38α specific siRNA were applied to HeLa cells.

Ref: Fan, Li, et al. "A novel role of p38α MAPK in mitotic progression independent of its kinase activity." Cell Cycle 4.11 (2005): 1616-1624.

Pubmed: 16258274

DOI: 10.4161/cc.4.11.2125

Research Highlights

Despite the considerable challenges faced in the creation of these inhibitors, MK2 is still regarded as a promising target for the treatment of inflammation and associated illnesses, as well as for preventing tumor metastasis and enhancing tumor susceptibility to chemotherapy.
Fiore, Mario, Stefano Forli, and Fabrizio Manetti. "Targeting mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2, MK2): medicinal chemistry efforts to lead small molecule inhibitors to clinical trials." Journal of medicinal chemistry 59.8 (2016): 3609-3634.
Pubmed: 26502061 DOI: 10.1021/acs.jmedchem.5b01457

According to this research, sophoridine presents a viable treatment option for preventing the growth of tumors in colorectal malignancies.
Wang, Rui, et al. "Sophoridine inhibits human colorectal cancer progression via targeting MAPKAPK2." Molecular Cancer Research 17.12 (2019): 2469-2479.
Pubmed: 31575657 DOI: 10.1158/1541-7786.MCR-19-0553